A worker at an Amgen research facility in South San Francisco has been hospitalized after a "flash fire" involving hazardous materials.
The drugmaker has been fined by the French Competition Authority for "disparaging" generic copies of its now-off-patent bloodthinner, Plavix.
The company didn't make any friends in Israel when local media reported tiny tax rates paid by the company. Coming as they did amid news of cost-cutting and layoffs, the tax figures stung--and sparked a public outcry, Haaretz notes. And now, Israeli Finance Minister Yair Lapid is in talks with Teva chief Jeremy Levin to work out a settlement.
Teva Pharmaceutical Industries' hot potato contraceptive drug Plan B One Step is getting tossed around some more, as a U.S. federal judge labeled the U.S government's position on it "intellectually dishonest."
A federal judge has told the FDA to do exactly what the agency tried to do two years ago: make the "morning after" birth control pill freely available to girls of all ages without a prescription.
A recall of four batches of a Teva Pharmaceutical Industries ($TEVA) generic drug has been updated in the U.K. because the original recall got batch numbers wrong.
On the eve of trial, Gilead Sciences ($GILD) and Teva Pharmaceutical Industries ($TEVA) struck a deal to wrap up their patent fight over Viread. If the settlement is approved, the generics maker will have the right to launch its version in December 2017.
Turns out, Teva Pharmaceutical Industries' ($TEVA) at-risk launch of copycat Protonix was really, really risky. The company now says it's looking at up to $2 billion in legal losses, to compensate Pfizer ($PFE) for lost profits on the drug.
A U.S. court has struck Baraclude from the patent list. The Bristol-Myers Squibb ($BMY) hepatitis B drug saw its composition of matter patent invalidated in a court fight with Teva Pharmaceutical Industries ($TEVA), which wants to sell its own version.
If Teva Pharmaceutical Industries investors are ticked off about its shortfall in fourth-quarter earnings, they might be appeased by its 15% dividend hike. No doubt that's the intent.